补肾通脉方通过调控microRNA-126-3p对血管内皮损伤的保护作用  

The Protective Effect of Bushen Tongmai Recipe(补肾通脉方)on Vascular Endothelial Injury by Regulating MicroRNA-126-3p

作　　者：陈宏昱 程红[1] 庄震坤 徐翀[1] 刘树楷 赵海梅 彭少林[1] 燕竹青[1] 陈颖颖 焦萁荟 程晶[1] CHEN Hong-yu;CHENG Hong;ZHUANG Zhen-kun;XU Chong;LIU Shu-kai;ZHAO Hai-mei;PENG Shao-lin;YAN Zhu-qing;CHEN Ying-ying;JIAO Qi-hui;CHENG Jing(The Fourth Clinical Medical College,Guangzhou University of Chinese Medicine/Shenzhen Hospital of Traditional Chinese Medicine,Shenzhen Guangdong 518033,China)

机构地区：[1]广州中医药大学第四临床医学院/深圳市中医院,广东深圳518033

出　　处：《中医药导报》2022年第2期7-12,共6页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：深圳市科技计划项目(JCYJ20180305163238685)。

摘　　要：目的:探究补肾通脉方通过调控miRNA-126-3p对血管内皮损伤的保护作用。方法:将15只普通级新西兰大白兔随机分为补肾通脉方组、阿托伐他汀组及正常组,每组5只,正常组正常饲养,补肾通脉方组及阿托伐他汀组给予相应药物灌胃,1次/d,7 d后获取正常兔血清及含药血清。取健康剖腹产新生婴儿脐带,分离并培养足够的人脐静脉内皮细胞(HUVEC),留取一部分细胞作正常对照组,其余细胞经质量浓度为50μg/mL的氧化低密度脂蛋白(ox-LDL)作用24 h后分为损伤对照组、补肾通脉方5%浓度组、补肾通脉方10%浓度组、补肾通脉方15%浓度组、阿托伐他汀5%浓度组、阿托伐他汀10%浓度组、阿托伐他汀15%浓度组。损伤对照组及正常对照组予正常兔血清干预,补肾通脉方组予不同浓度补肾通脉方含药血清干预,阿托伐他汀组予不同浓度阿托伐他汀含药血清干预。CCK-8法检测细胞活性;qPCR法检测各组miRNA-126-3p的表达水平。结果:与正常对照组比较,损伤对照组、补肾通脉方5%浓度组、补肾通脉方15%浓度组、阿托伐他汀5%浓度组及阿托伐他汀15%浓度组细胞活性均明显降低(P<0.05);与损伤对照组比较,补肾通脉方5%、10%、15%浓度组及阿托伐他汀10%、15%浓度组细胞活性均明显升高(P<0.05);与补肾通脉方10%浓度组比较,补肾通脉方5%、15%浓度组细胞活性均明显降低(P<0.05);与阿托伐他汀10%浓度组比较,阿托伐他汀5%、15%浓度组细胞活性均明显降低(P<0.05)。qPCR结果显示,与损伤对照组比较,补肾通脉方组HUVEC细胞中miRNA-126-3p相对表达量明显上调(P<0.05),补肾通脉方组HUVEC细胞中miRNA-126-3p相对表达量与阿托伐他汀组比较,差异无统计学意义(P>0.05)。结论:补肾通脉方能够通过上调miRNA-126-3p的表达水平发挥对内皮细胞损伤的保护作用。Objective:To explore the protective effect of Bushen Tongmai Recipe(BSTMR)on endothelial injury by regulating mirNA-126-3p.Methods:15 normal New Zealand white rabbits were randomly divided into BSTMR group,atorvastatin group and normal group,with 5 rabbits in each group.The normal group was fed normally,the BSTMR group and atorvastatin group were given corresponding drugs by gavage,once a day,and the normal rabbit serum and drug containing serum were obtained after 7 days.Take the umbilical cord of healthy newborn infants delivered by caesarean section,isolate and culture enough human umbilical vein endothelial cells(HUVEC),and leave some cells as the normal control group.The remaining cells were treated with oxidized low-density lipoprotein(ox-LDL)at a concentration of 50μg/mL for 24 h and divided into injury control group,BSTMR 5%group,BSTMR 10%group,BSTMR 15%group,atorvastatin 5%group,atorvastatin 10%group and atorvastatin 15%group.The injured control group and normal control group were treated with normal rabbit serum,the BSTMR group was treated with different concentrations of BSTMR containing serum,and the atorvastatin group was treated with different concentrations of atorvastatin containing serum.Cell activity was detected by CCK-8 method.The expression levels of miRNA-126-3p in each group were detected by qPCR.Results:Compared with normal control group,the cell activity of injury control group,BSTMR 5%group,BSTMR 15%group,atorvastatin 5%group and atorvastatin 15%group decreased significantly(P<0.05).Compared with injury control group,BSTMR 5%,10%,15%concentration groups and atorvastatin 10%,15%concentration groups had higher cell activity,the difference was statistically significant(P<0.05).Compared with BSTMR 10%concentration group,the cell activity of BSTMR 5%and 15%concentration groups decreased significantly(P<0.05).Compared with the atorvastatin 10%concentration group,the cell activity of atorvastatin 5%and 15%concentration groups decreased significantly(P<0.05).qPCR results showed that compared wi

关 键 词：动脉粥样硬化 血管内皮损伤 补肾通脉方 阿托伐他汀 内皮保护 miRNA-126-3p 兔 人脐静脉内皮细胞 

分 类 号：R285.5[医药卫生—中药学]